These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: New dosing of ddI (Videx) and Nelfinavir (Viracept) approved.
    Author: Highleyman L.
    Journal: BETA; 1999; 12(4):3. PubMed ID: 11367246.
    Abstract:
    The Food and Drug Administration (FDA) approved once-daily dosing of a new 200mg formulation of Bristol-Myers Squibb's nucleoside analog, ddI. The new tablet will be available in December 1999. Two tablets of ddI must always be taken together to minimize gastric acid degradation. The FDA will require the drug company to warn patients of the increased risk of developing pancreatitis, sometimes observed in persons on ddI therapy. The FDA also approved a 1,250mg twice-daily dosing of nelfinavir, a protease inhibitor manufactured by Agouron Pharmaceuticals.
    [Abstract] [Full Text] [Related] [New Search]